Prions adopt alternative, self-replicating protein conformations and thereby determine novel phenotypes that are often irreversible. Nevertheless, dominant-negative prion mutants can revert phenotypes associated with some conformations. These observations suggest that, while intervention is possible, distinct inhibitors must be developed to overcome the conformational plasticity of prions. To understand the basis of this specificity, we determined the impact of the G58D mutant of the Sup35 prion on three of its conformational variants, which form amyloids in S. cerevisiae. G58D had been previously proposed to have unique effects on these variants, but our studies suggest a common mechanism. All variants, including those reported to be resistant, are inhibited by G58D but at distinct doses. G58D lowers the kinetic stability of the associated amyloid, enhancing its fragmentation by molecular chaperones, promoting Sup35 resolubilization, and leading to amyloid clearance particularly in daughter cells. Reducing the availability or activity of the chaperone Hsp104, even transiently, reverses curing. Thus, the specificity of inhibition is determined by the sensitivity of variants to the mutant dosage rather than mode of action, challenging the view that a unique inhibitor must be developed to combat each variant.
Author summary
Prion proteins adopt alternative conformations and assemble into amyloid fibers, which have been associated with human disease. These fibers are highly stable and self-replicate, leading to their persistence and resulting in a set of progressive and often fatal disorders. Inhibitors have been shown to interfere with some conformations but not others, suggesting that distinct strategies must be developed to target each. However, we show here that a single dominant-negative mutant can inhibit multiple conformations of the same prion protein through the same pathway but at distinct doses. Thus, the basis of this specificity a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Introduction
Alternative, self-replicating protein conformations have emerged as bona fide parallel proteinfolding trajectories with significant biological consequences [1] . In most cases, these alternative conformations are β-sheet-rich and self-assembling, forming linear amyloid aggregates [2] . These amyloids replicate the conformation of their constituent monomers by acting as templates to direct the refolding of other conformers of the same protein as they are bound by and incorporated into the growing aggregate. In so doing, the majority of the protein is converted to the alternative conformation, changing protein activity and thereby inducing new phenotypes, such as neurodegenerative diseases (i.e., Transmissible Spongiform Encephalopathies or prion diseases, Alzheimer's and Huntington's diseases) and organelle biogenesis in mammals and gene expression regulation in single-celled organisms [1, 3] . The high efficiency of this process, when combined with the high kinetic stability of the aggregates [2] , contributes to the recalcitrance of amyloids to clearance by protein quality control pathways [4] . As a result, the associated phenotypes are frequently difficult-if not impossible-to reverse, especially in the clinic [5] .
One notable exception to the persistence of amyloid-associated phenotypes is their reversal or "curing" by dominant-negative mutants of prion proteins. These sequence variants were first identified by their ability to confer resistance to scrapie in sheep (Q171R or R154H in the mammalian prion protein PrP), sporadic Creutzfeldt-Jakob disease (sCJD) in humans (E219K in PrP), and translation termination infidelity in yeast (G58D in Sup35) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Subsequently, these mutants were shown to interfere with the assembly of amyloid by the wildtype prion protein in vitro and to reduce or clear existing amyloid composed of the wildtype prion protein when delivered to tissue culture cells, mice, or yeast [15, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Given this unique curing ability, elucidating the mechanism(s) by which dominant-negative prion mutants act may reveal potential strategies for reversing amyloid persistence more generally.
Despite the promise of this line of investigation, the inhibition achieved by dominant-negative mutants appears to be conformation-specific. For example, the resistance to sCJD conferred by the E219K PrP mutant in humans is not extended to the conformations, known as variants, responsible for genetic and iatrogenic forms of the disease [14, 15, 17, [32] [33] [34] [35] . Similarly, resistance to classical scrapie is not observed for bovine spongiform encephalopathy (BSE) or atypical scrapie variants in sheep with Q171R or R154H mutations in PrP [10, [36] [37] [38] [39] [40] [41] [42] [43] [ [44] [45] [46] [47] [48] [49] [50] [51] [52] [53, 54] .
What is the molecular basis of this differential inhibition? One possibility is that the distinct recognition surfaces and/or rate-limiting steps in the self-replication process characteristic of the variants make them susceptible to only certain mechanisms of inhibition [55] [56] [57] [58] [59] [60] [61] . Alternatively, the conformational differences may confer distinct sensitivities to the same mechanism of inhibition. Given the conformational plasticity of amyloidogenic proteins [62, 63] , understanding the forces limiting the efficacy of inhibitors can mean the difference between developing an infinite number of individual interventions for each variant or simply different dosing regimes for the same inhibitor. ) to expression of G58D and the impact of this dominant-negative mutant on the self-replication of each variant. Our studies indicate that "resistance" to G58D can be partially overcome at higher dosage of the mutant, revealing differential sensitivity to the inhibition. G58D reduces the kinetic stabilities of the amyloids associated with the variants, which determines their efficiencies of fragmentation by chaperones [60] . Consistent with this correlation, G58D inhibition of the three variants was dependent on the chaperone Hsp104, as was the case for the previously studied [PSI + ] Strong variant [64] . In the presence of G58D, Sup35 amyloid was fragmented by Hsp104 with higher efficiency. This increase led to amyloid clearance in daughter cells, which could be reversed by transient inhibition of Hsp104 specifically in this population. Thus, G58D dominant-negative inhibition targets distinct conformational variants through the same mechanism with differing efficacy, suggesting that the observed "resistance" is relative rather than absolute. Weak variants, which were previously reported to be compatible with G58D expression [53, 54] , efficient prion propagation was also dependent on the ratio of wildtype to G58D, but the critical threshold for phenotypic reversal was distinct in each case. Fig 1E) were more unstable, consistent with the stronger reversal of their prion phenotypes at this ratio (Fig 1A and 1B) . For the [64] , differ in their sensitivities to G58D inhibition (Fig 1) , the dose dependence of this inhibition suggests a common underlying mechanism [64, 68] . We previously linked G58D inhibition to a reduction in the kinetic stability of Sup35 aggregates and a resulting increase in their fragmentation by the chaperone Hsp104, which led to their disassembly [64] conformation, the relative stabilities of the four variants have not been previously reported [60, 69, 70] .
Results
To gain this insight, we first determined the kinetic stabilities of Sup35 aggregates, in the absence of G58D, by their sensitivity to disruption with 2% SDS at different temperatures as a baseline comparison [71] . Solubilized protein is then quantified by entry into a SDS-polyacrylamide gel and immunoblotting [64] [60, 72] . To sensitize the assay in an attempt to reveal biochemical differences between the variants in each group, we deleted the NATA N-terminal acetyltransferase, which reduces the kinetic stability of Sup35 amyloid in [PSI + ] strains [73, 74] . If G58D inhibits these variants through a common mechanism, we would expect the kinetic stabilities of each of the variants to decrease in the presence of the mutant. To test this possibility, we assessed the sensitivity of Sup35 aggregates, isolated from diploid strains expressing a 1:1 ratio of wildtype to G58D, to disruption with 2% SDS at different temperatures. ] variants in a manner that correlates directly with the severity of their phenotypic inhibition (Fig 1) . These observations are consistent with the idea that G58D acts through a similar mechanism to inhibit the [PSI + ] variants. shifted to smaller complexes at the lowest wildtype to G58D ratio tested (1:2, Fig 3F) . Together, these observations suggest that the kinetic destabilization of Sup35 aggregates by G58D results in a higher efficiency of fragmentation in vivo, and these effects correlate directly with the severity of their phenotypic inhibition (Fig 1) .
To determine how the kinetic destabilization of Sup35 aggregates by G58D impacts the number of heritable prion units (propagons) [75] . Specifically, diploid strains expressing either two copies of wildtype SUP35 or one copy each of wildtype SUP35 and G58D were treated with guanidine HCl (GdnHCl), a potent inhibitor of the fragmentation catalyst Hsp104 [67, [76] [77] [78] [79] [80] [81] , allowed to dilute existing aggregates through cell division, and plated in the absence of the inhibitor to quantify the number of cells inheriting an aggregate. As upon G58D expression to much higher levels [53] . Phenotypic strengthening is associated with a decrease in soluble Sup35, which would result from an increase in amyloid templates, detected as propagons in this assay, through enhanced fragmentation [60] . Thus, the phenotypic consequences of G58D expression, both inhibition and enhancement, can be directly explained by changes in the steady-state accumulation of Sup35 propagons. Given the distinct kinetic stabilities of Sup35 amyloid in the [PSI + ] variants studied here (Fig 2) , the specificity of G58D inhibition and enhancement likely reflect thresholds for fragmentation activity that result in changes in the steady-state accumulation of Sup35 forms in vivo.
If enhanced fragmentation is indeed the mechanism underlying G58D effects, these changes should be Hsp104-dependent. To determine if this is the case, we constructed heterozygous disruptions of HSP104 in diploid strains expressing G58D at different ratios (S3 Fig) (Fig 3G and 3I, compare lanes 2 and 4) . Thus, the reduction in propagon number associated with G58D is suppressed by lowering the dosage of HSP104 and thereby fragmentation activity, suggesting that enhanced fragmentation is the underlying mechanism.
Next, we determined if these changes in propagon number upon heterozygous disruption of HSP104 impacted the severity and stability of the (Fig 1B and 1C) ] loss in all strains, indicating that wildtype fragmentation levels must be close to the threshold required for efficient propagation of the amyloid state (Fig 1E) . Nonetheless, in the strain expressing the 1:2 ratio of wildtype to G58D, the frequency of [PSI + ] loss was suppressed by heterozygous disruption of Hsp104 (Fig 1E) . 
Hsp104 mediates G58D inhibition by promoting Sup35 aggregate disassembly
The enhanced efficiency of fragmentation of Sup35 aggregates in the presence of G58D (Fig  3D and 3E ) and the reduction in propagon levels (Fig 3G and 3H) [64] , suggesting that release of soluble Sup35 from aggregates by enhanced fragmentation may be less readily detected in the latter variants. Specifically, the individual steps in prion propagation in vivo (e.g. conversion, fragmentation, and transmission) are variant-specific and difficult to monitor in isolation in a living system [60, 78] . Moreover, the accumulation of soluble Sup35 is impacted not only by the inherent rate of conversion on fibers ends but also by the cumulative effect of each of the steps of prion propagation on the number of those ends [60, 72] . Because the cumulative effects of each event on soluble Sup35 levels are not intuitive to qualitatively predict from those rates, we developed a deterministic model of Sup35 dynamics to deconstruct this complexity and gain additional mechanistic insight into the differential effects of G58D on the variants. This model uses a range of conversion and fragmentation rates that support [PSI + ] maintenance to capture different variants (see S1 Text). In addition, we have incorporated the concept of nucleation, which specifies a minimum size for a thermodynamically stable aggregate and has been previously established as a key event in Sup35 aggregation in vitro [82] [83] [84] .
The steady-state size and number of Sup35 aggregates reflects a balance between conversion, which depends on continuous synthesis of Sup35, and fragmentation [72] ; when Sup35 synthesis is halted, aggregates are predicted to increase in number (Fig 4A) and decrease in size (Fig 4B) because fragmentation is proposed to exert a greater influence on the equilibrium state [72] . In line with this observation, our model predicts that cycloheximide treatment will decrease soluble Sup35 levels for prion variants that are stably propagating [PSI + ] (Fig 4C) because additional templates have been created (Fig 4A) . Intriguingly, the extent of this decrease is predicted in our mathematical model to correspond inversely with the rate of fragmentation: that is, the slowest rate of fragmentation induces the largest decrease in soluble Sup35 (Fig 4B, black) , relative to the steady-state levels prior to the manipulation. If fragmentation produces more templates, which in turn promotes Sup35 conversion to the amyloid state, why would we predict a lower rate of fragmentation to have the most significant effect on soluble Sup35 levels? The reason is, as we have previously demonstrated under heat shock conditions [85] , fragmentation resolubilizes Sup35 in addition to creating new templates. Thus, high rates of fragmentation will push the balance between conversion and fragmentation toward the latter, causing a shift from aggregated to soluble Sup35. Consistent with this logic, our model predicts an increase in aggregate number that corresponds inversely with fragmentation rate (i.e. the largest increase in aggregate number corresponds to the slowest fragmentation rate; Fig 4A, black) . This correlation can be explained directly by changes in the rate of Sup35 resolubilization from aggregates: the slowest fragmentation rate leads to the slowest rate of resolubilization (Fig 4D, black) and thereby the largest increase in aggregate number (Fig 4A, black) . (Fig 5A-5C (Fig 5D-5F , lane 1). According to our model, these observations are consistent with a nucleation-dependent aggregation process, which permits resolubilization of aggregates that are fragmented below the minimum thermodynamically stable size (Fig 4D, compare solid and dashed , which would release more aggregated Sup35 into the soluble pool (Fig 4D, red) (Fig 5E and 5F, compare lanes 1 and 3) , suggesting that G58D expression promotes aggregate fragmentation and thereby resolubilization. Consistent with this idea, treatment of the variants with both cycloheximide and guanidine HCl led to an increase in aggregate size (Fig 5A-5C ) and a decrease in soluble Sup35 levels in the presence of G58D (Fig 5D-5F, compare lanes 3 and 4) , indicating that Hsp104-catalyzed fragmentation promotes Sup35 resolubilization.
The ability of our mathematical model to capture the behavior of Sup35 in response to these manipulations strongly supports the idea that G58D destabilizes Sup35 aggregates to promote their increased fragmentation by Hsp104 and thereby their resolubilization. However, a more nuanced evaluation indicates that the threshold for inhibition cannot be explained by fragmentation efficiency alone. (Fig 1) but a (Fig 2 and S2 Fig). A bulk shift in Sup35 from aggregate to soluble requires that the resolubilized Sup35 does not efficiently reconvert to the aggregated state; thus, conversion efficiencies will also impact the outcome of the G58D effects on aggregate kinetic stability, fragmentation and resolubilization. 
G58D promotes Sup35 aggregate disassembly in daughter cells
Together, our studies are consistent with the ideas that resolubilization of aggregated Sup35 is the mechanism of G58D inhibition and that the variant-specific rates of conversion and fragmentation dictate the threshold for phenotypic reversal. However, Weissman and colleagues previously reported that loss of [PSI + ] Sc4 propagated by G58D alone was associated with propagon loss from daughter but not mother cells [54] . This observation was interpreted as a G58D-dependent defect in Sup35 aggregate transmission to daughter cells, but using a direct fluorescence-based microscopy assay for Sup35-GFP transmission, we were unable to detect a transmission defect in [ Sc4 propagation is unstable in a wildtype strain (~50% prion loss), but we found that this instability is strongly suppressed by heterozygous disruption of HSP104 (~5% prion loss; Fig 6A) .
Propagons are normally distributed between mother and daughter cells in a 2:1 ratio [75] . However, analysis of propagon numbers in mother and daughter cells showed an even stronger bias in the distribution of propagons toward the mothers in the presence of G58D (Fig 6B,  black diamonds) , including a population of pairs in which the mother but not the daughter retained a large number of propagons (Fig 6B, red diamonds) . By contrast, heterozygous disruption of HSP104 reduced the stronger mother bias associated with G58D expression, and more propagons were detected in daughter cells (Fig 6B, white triangles) . Notably, daughter cells lacking propagons were not isolated from the HSP104 heterozygous disruption strain, indicating that the suppression of prion loss (Fig 6A) correlated with an increase in propagons in daughter cells (Fig 6B) .
Given the suppression of these phenotypes by heterozygous disruption of Hsp104, we next directly determined if Hsp104 inhibition specifically in daughter cells is sufficient to suppress (Fig 6C and S5 Fig). The isolated daughters were then incubated on rich medium in the presence or absence of GdnHCl for three hours to transiently inhibit Hsp104 activity and then plated to determine the frequency of prion loss. Strikingly, GdnHCl treatment of daughter cells suppressed the frequency of prion loss (Fig 6D) . Because daughter cells were biochemically isolated before treatment, the GdnHCl suppression of prion loss cannot be explained by an increased transmission of Sup35 aggregates to daughter cells upon Hsp104 inhibition. Weak , through the same mechanism. The effects of G58D expression are most easily detected at the protein level as kinetic destabilization of Sup35 amyloid (Fig 3A-3C ) and related reductions in the size of their SDS-resistant core polymers (Fig  3D-3F) . These changes only become apparent at the phenotypic and inheritance levels when the impact on Sup35 amyloid rises above a threshold dictated by the rates of conversion and fragmentation for the variants, allowing disassembly to dominate over reassembly.
The G58D mutation lies in the second oligopeptide repeat of Sup35, a region of the protein that is essential for prion propagation [86] [87] [88] and that impacts the ability of the Hsp104 chaperone to thread monomers through its central pore during the fragmentation process [89] . [69] . Nonetheless, the kinetic destabilization of the four variants by G58D (Fig 3A-3C ) [64] suggests this region contributes directly to associations within each of the aggregates. Structural studies on the isolated second repeat revealed that the G58D substitution introduced a turn into the otherwise extended conformation of the wildtype repeat, suggesting that packing and thereby amyloid kinetic stability could be altered by this conformational change [90] .
Previous studies on the , curing depended not only on the dosage of G58D but also of HSP104, suggesting that prion propagation was inhibited by amyloid disassembly. Indeed, in the presence of G58D, previously aggregated Sup35 , curing correlated with the loss of heritable aggregates in daughter cells, interpreted as a G58D-induced defect in amyloid transmission [54] . These distinct models for inhibition are consistent with the idea that different conformational variants must be cured through different molecular mechanisms [62, 63] . However, our studies resolve this controversy: G58D inhibits both variants by promoting amyloid disassembly in daughter cells. This model is supported by both the Hsp104-dependence of the curing of both variants (Fig 1D) [64] and of the reduction in propagons (Fig 3H) [64] . In addition, overexpression of Hsp104 cures [PSI + ] Sc4 propagated by G58D but not wildtype Sup35, suggesting the former is more sensitive to higher fragmentation rates than the latter [54] . Consistent with this interpretation, overexpression of an N-terminally truncated Hsp104 mutant [54] , which is deficient in substrate processing [91] , is unable to cure [PSI + ] Sc4 propagated by G58D.
We have previously drawn parallels between the dominant-negative inhibition of [PSI + ] propagation by Sup35 G58D and that of protease-resistant PrP by hamster Q219K (corresponding to E219K in humans and Q218K in mouse). In both cases, the mutant is incorporated into wildtype aggregates but capable of destabilizing the amyloid state only when present in excess to wildtype protein, and the efficacy of dominant-negative inhibition is greater for less kinetically stable conformational variants [15, 20, 21, 64, 92] . Given the likelihood that the mechanisms of inhibition are similar between the yeast and mammalian dominant-negative mutants, the "resistance" of sCJD to E219K in humans and of 22L to Q219K in mice may be possible to overcome by increasing the dosage of the mutant, as we have demonstrated here for G58D and [PSI + ] Sc37 (Fig 1B and 1E ). For G58D, inhibition occurs at a dosage far below that at which the prion state is induced to appear [53] , indicating that the threshold between curing and induction is wide enough to accommodate switches in one direction or the other specifically. A similar analysis in mammals would be prudent before pursuing increased dosage of dominant-negative mutants as a therapeutic strategy.
How can the absence of heritable aggregates in some daughter cells be reconciled with amyloid disassembly as a common mechanism of inhibition for G58D? Our previous studies have revealed that increasing chaperone levels by heat shock, leads to amyloid disassembly in a [PSI + ] Weak strain [85] , suggesting that the ratio of chaperones:amyloid is a key contributor to the balance between amyloid assembly and disassembly. A similar skew in this ratio likely occurs during G58D curing but through a distinct mechanism. Our previous studies uncovered a size threshold for amyloid transmission during yeast cell division: larger aggregates were preferentially retained in mother cells [72] . This asymmetry created an age-dependent difference in aggregate load, with newborn daughters taking several generations to return to the steady-state level of propagons observed in mother cells [72] . This observation suggests that the chaperone:substrate ratio could be skewed toward the former in daughter cells. This altered ratio, when combined with the decrease in the kinetic stability of Sup35 amyloid induced by G58D (Fig 3A-3C ] by promoting amyloid disassembly, curing is reduced (Fig 5A) , and propagon numbers increase in daughters (Fig 5B) when Hsp104 levels are reduced. Most importantly, transiently blocking Hsp104 activity in daughter cells after division also greatly reduces prion loss (Fig 5D) . Thus, G58D-containing Sup35 amyloid is transmitted to daughter cells, but, once there, these aggregates are at greater risk of clearance by Hsp104-mediated disassembly.
Beyond dominant-negative mutants, conformational variants of PrP and Sup35 also differ in their sensitivities to small molecule inhibitors [62, 63] . Unfortunately, even sensitive conformational variants can develop resistance to these compounds, further complicating attempts to develop therapeutic interventions for these diseases. For example, treatment of prion-infected mice or tissue culture cells with quinacrine or swainsonine reduced the kinetic stability of protease-resistant PrP and altered its tropism in cell lines, but these properties were reversed when treatment was removed [93] [94] [95] . Although it remains unclear whether the emerging conformational variants were minor components that were selected or newly induced by the treatment, this conformational plasticity creates a moving target that is impossible to manage if a unique inhibitor must be developed in each case. Our studies suggest that as prion conformational variants evolve, adapt or mutate, changes in dosing regimes could be effective countermeasures, although the range of possible doses is likely to be restricted because overexpression of even a dominant-negative mutant can lead to prion appearance [53] . Nevertheless, quinacrine can eliminate the RML conformational variant of PrP from CAD5 cells at a 5-fold lower dosage than is required to eliminate an IND24-resistant variant [96] .
Much research is focused on the appearance and self-replicating amplification of amyloid, yet these processes are clearly counteracted by disassembly pathways in vivo. This balance between assembly and disassembly contributes strongly to prion persistence, even in mammals. For example, inhibition of PrP expression can reverse accumulation of protease-resistant PrP, pathological changes and clinical progression of prion disease in mice, presumably by allowing clearance pathways to dominate, if initiated before extensive damage arises [97] . While mammals lack an Hsp104 homolog, a chaperone system, composed of mammalian Hsp70, Hsp110, and class A and B J-proteins, possesses strong disaggregase activity [98] , capable of directing amyloid disassembly, although this activity has yet to be tested against protease-resistant PrP [99] . Nevertheless, natural variations in the accumulation of prion and chaperone proteins may also serve as a new framework in which to consider phenotypic differences among variants. For example, tropism and clinical progression are likely to be impacted by the balance between assembly and disassembly pathways, as we have observed for mitotic stability and heat shock-induced prion curing in yeast [72, 85] . Moreover, the steady-state ratio of chaperones:amyloid may be a key consideration in screening potential therapeutics and in their ultimate efficacy in vivo, particularly for small molecules proteostasis regulators that perturb the assembly/disassembly balance.
Methods Plasmids
All plasmids used in this study are listed in S1 Table. pRS306-P ADH contains P ADH -Multiple Cloning Site-T CYC1 as a KpnI-SacI fragment from pSM556 (a gift from F.U. Hartl) in a similarly digested pRS306. The SUP35(G58D) ORF was then subcloned into pRS306-P ADH as a BamHI-EcoRI fragment isolated from pRS306-SUP35(G58D) to create pRS306-P ADH SUP35 (G58D) (SB468).
Oligonucleotides
Oligonucleotides used in this study are listed in S2 Table. Yeast strains All strains are derivatives of 74-D694 and are listed in S3 FP36) were generated by transformation of PCR-generated cassettes using pFA6aKanMX4 as a template with the indicated oligonucleotide primers (S2 Table) and selection on rich medium supplemented with G418. HSP104 disruptions were generated by transformation with a PvuI-BamHI fragment of pYABL5 (a gift from S. Lindquist) and selection on minimal medium lacking leucine. Disruptions of NAT1 (FP29, FP30) were generated by transformation of PCR-generated cassettes using pFA6a-hphMX4 as a template with the indicated primers (S2 Table) and selection on complete medium supplemented with hygromycin. All the disruptions were verified by PCR and 2:2 segregation of the appropriate marker.
Prion loss
Exponentially growing cultures of the indicated strain were plated on YPD for single colonies, and the frequency of [PSI + ] loss was determined by the number of red colonies arising.
Protein analysis
Semidenaturing detergent agarose gel electrophoresis (SDD-AGE), SDS-PAGE, quantitative immunoblotting and SDS-sensitivity experiments were performed as previously described [73] . To analyze the fate of aggregated Sup35, cultures were grown to midlog phase and treated with cycloheximide (CHX) or both CHX and guanidine HCl (GdnHCl) for 1.7 hours. Yeast lysates were collected before and after treatment and incubated at 53˚C and 100˚C in the presence of 2% SDS before analysis by SDS-PAGE. Lysates were also prepared from the same cultures and analyzed by SDD-AGE.
Propagon counts
The number of propagons per cell was determined using a previously described in vivo dilution, colony-based method [75] . For propagon counting in mothers and daughters, a pair of mother and daughter cells was separated by micromanipulation onto minimal medium (SDcomplete with 2.5mM adenine and 4% dextrose) with 3mM GdnHCl. After growing at 30˚C for about 48 h, whole colonies were isolated using a cut pipette tip, resuspended in a small volume of water and plated onto YPD plates. The number of white colonies was then counted.
Daughter-specific assays
Daughters were separated by FACS based on bud-scar labeling. Yeast cells were incubated for 1 h at room temperature in 1μg/ml Alexa-647 wheat germ agglutinin (WGA) in PBS. After washing twice in PBS, cells with the lowest fluorescence intensity (5%) were sorted as newborn daughter cells, and a sample of this fraction was viewed by fluorescence microscopy to confirm bud scar number. This fraction was also moved to rich medium (1/4 YPD) for color development. For Hsp104 inhibition, sorted fractions were first moved to a minimal medium with 3mM GdnHCl for three hours before being transferred to rich medium. In each case only completely red colonies were counted as [psi -].
Fluorescence microscopy
Fluorescence microscopy was performed on a DeltaVision deconvolution microscope equipped with a 100x objective. WGA Alexa-647 fluorescence was collected using 650nm excitation and 668nm emission wavelengths and with an exposure of 50ms. Images were processed in ImageJ software.
Propagon recovery
Cultures were grown in YPAD medium to an OD 600 of 0.1 at 30˚C. GdnHCl was added to 3mM, and the culture was returned to 30˚C for 5 hours to decrease the propagon number. Cultures were then collected by centrifugation, washed and transferred to YPAD medium without GdnHCl for recovery. Samples were plated on YPD, and the number of propagons per cell was counted at the indicated timepoints. 
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